Lucid Diagnostics Inc.

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, ABT has a market cap of 230.8B. Regarding current trading prices, LUCD is priced at $1.10, while ABT trades at $132.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas ABT's P/E ratio is 16.63. In terms of profitability, LUCD's ROE is -4.04%, compared to ABT's ROE of +0.32%. Regarding short-term risk, LUCD is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check ABT's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, LUCD is priced at $1.10, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, LUCD's ROE is -4.04%, compared to BSX-PA's ROE of +0.12%. Regarding short-term risk, LUCD is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check BSX-PA's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, BSX has a market cap of 157.3B. Regarding current trading prices, LUCD is priced at $1.10, while BSX trades at $106.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas BSX's P/E ratio is 63.18. In terms of profitability, LUCD's ROE is -4.04%, compared to BSX's ROE of +0.12%. Regarding short-term risk, LUCD is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check BSX's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, SYK has a market cap of 150.7B. Regarding current trading prices, LUCD is priced at $1.10, while SYK trades at $394.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas SYK's P/E ratio is 52.13. In terms of profitability, LUCD's ROE is -4.04%, compared to SYK's ROE of +0.14%. Regarding short-term risk, LUCD is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check SYK's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, MDT has a market cap of 118.7B. Regarding current trading prices, LUCD is priced at $1.10, while MDT trades at $92.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas MDT's P/E ratio is 25.60. In terms of profitability, LUCD's ROE is -4.04%, compared to MDT's ROE of +0.10%. Regarding short-term risk, LUCD is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check MDT's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, EW has a market cap of 48B. Regarding current trading prices, LUCD is priced at $1.10, while EW trades at $81.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas EW's P/E ratio is 34.24. In terms of profitability, LUCD's ROE is -4.04%, compared to EW's ROE of +0.41%. Regarding short-term risk, LUCD is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check EW's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, DXCM has a market cap of 32.3B. Regarding current trading prices, LUCD is priced at $1.10, while DXCM trades at $82.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas DXCM's P/E ratio is 57.93. In terms of profitability, LUCD's ROE is -4.04%, compared to DXCM's ROE of +0.26%. Regarding short-term risk, LUCD is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check DXCM's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, PHG has a market cap of 26.3B. Regarding current trading prices, LUCD is priced at $1.10, while PHG trades at $28.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas PHG's P/E ratio is 149.13. In terms of profitability, LUCD's ROE is -4.04%, compared to PHG's ROE of +0.01%. Regarding short-term risk, LUCD is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check PHG's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, STE has a market cap of 24.8B. Regarding current trading prices, LUCD is priced at $1.10, while STE trades at $251.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas STE's P/E ratio is 38.53. In terms of profitability, LUCD's ROE is -4.04%, compared to STE's ROE of +0.10%. Regarding short-term risk, LUCD is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check STE's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, PODD has a market cap of 23.3B. Regarding current trading prices, LUCD is priced at $1.10, while PODD trades at $330.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas PODD's P/E ratio is 101.46. In terms of profitability, LUCD's ROE is -4.04%, compared to PODD's ROE of +0.18%. Regarding short-term risk, LUCD is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check PODD's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, ZBH has a market cap of 21.3B. Regarding current trading prices, LUCD is priced at $1.10, while ZBH trades at $107.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas ZBH's P/E ratio is 26.28. In terms of profitability, LUCD's ROE is -4.04%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, LUCD is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check ZBH's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, LUCD is priced at $1.10, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas ABMD's P/E ratio is 65.36. In terms of profitability, LUCD's ROE is -4.04%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, LUCD is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check ABMD's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, SNN has a market cap of 16.4B. Regarding current trading prices, LUCD is priced at $1.10, while SNN trades at $37.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas SNN's P/E ratio is 33.79. In terms of profitability, LUCD's ROE is -4.04%, compared to SNN's ROE of +0.09%. Regarding short-term risk, LUCD is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check SNN's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, LUCD is priced at $1.10, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas SWAV's P/E ratio is 78.76. In terms of profitability, LUCD's ROE is -4.04%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, LUCD is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check SWAV's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, ALGN has a market cap of 10.8B. Regarding current trading prices, LUCD is priced at $1.10, while ALGN trades at $149.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas ALGN's P/E ratio is 25.25. In terms of profitability, LUCD's ROE is -4.04%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, LUCD is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check ALGN's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, PEN has a market cap of 10.3B. Regarding current trading prices, LUCD is priced at $1.10, while PEN trades at $264.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas PEN's P/E ratio is 70.31. In terms of profitability, LUCD's ROE is -4.04%, compared to PEN's ROE of +0.12%. Regarding short-term risk, LUCD is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check PEN's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, GMED has a market cap of 8.4B. Regarding current trading prices, LUCD is priced at $1.10, while GMED trades at $62.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas GMED's P/E ratio is 24.24. In terms of profitability, LUCD's ROE is -4.04%, compared to GMED's ROE of +0.09%. Regarding short-term risk, LUCD is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check GMED's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, BIO has a market cap of 8.2B. Regarding current trading prices, LUCD is priced at $1.10, while BIO trades at $303.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas BIO's P/E ratio is 27.41. In terms of profitability, LUCD's ROE is -4.04%, compared to BIO's ROE of +0.05%. Regarding short-term risk, LUCD is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check BIO's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, BIO-B has a market cap of 6.7B. Regarding current trading prices, LUCD is priced at $1.10, while BIO-B trades at $247.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas BIO-B's P/E ratio is -3.23. In terms of profitability, LUCD's ROE is -4.04%, compared to BIO-B's ROE of +0.05%. Regarding short-term risk, LUCD is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check BIO-B's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, IRTC has a market cap of 5.4B. Regarding current trading prices, LUCD is priced at $1.10, while IRTC trades at $169.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas IRTC's P/E ratio is -57.92. In terms of profitability, LUCD's ROE is -4.04%, compared to IRTC's ROE of -1.05%. Regarding short-term risk, LUCD is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check IRTC's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, GKOS has a market cap of 5.4B. Regarding current trading prices, LUCD is priced at $1.10, while GKOS trades at $94.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas GKOS's P/E ratio is -58.49. In terms of profitability, LUCD's ROE is -4.04%, compared to GKOS's ROE of -0.13%. Regarding short-term risk, LUCD is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check GKOS's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, BRKR has a market cap of 5.4B. Regarding current trading prices, LUCD is priced at $1.10, while BRKR trades at $35.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas BRKR's P/E ratio is 68.35. In terms of profitability, LUCD's ROE is -4.04%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, LUCD is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check BRKR's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, LUCD is priced at $1.10, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas NARI's P/E ratio is -59.24. In terms of profitability, LUCD's ROE is -4.04%, compared to NARI's ROE of -0.17%. Regarding short-term risk, LUCD is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check NARI's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, TMDX has a market cap of 4.1B. Regarding current trading prices, LUCD is priced at $1.10, while TMDX trades at $119.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas TMDX's P/E ratio is 60.23. In terms of profitability, LUCD's ROE is -4.04%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, LUCD is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check TMDX's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, ITGR has a market cap of 3.9B. Regarding current trading prices, LUCD is priced at $1.10, while ITGR trades at $110.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas ITGR's P/E ratio is 47.30. In terms of profitability, LUCD's ROE is -4.04%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, LUCD is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check ITGR's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, LUCD is priced at $1.10, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas AXNX's P/E ratio is -709.80. In terms of profitability, LUCD's ROE is -4.04%, compared to AXNX's ROE of -0.02%. Regarding short-term risk, LUCD is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check AXNX's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, LIVN has a market cap of 3.1B. Regarding current trading prices, LUCD is priced at $1.10, while LIVN trades at $55.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas LIVN's P/E ratio is -14.41. In terms of profitability, LUCD's ROE is -4.04%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, LUCD is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check LIVN's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, INSP has a market cap of 2.8B. Regarding current trading prices, LUCD is priced at $1.10, while INSP trades at $95.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas INSP's P/E ratio is 55.21. In terms of profitability, LUCD's ROE is -4.04%, compared to INSP's ROE of +0.08%. Regarding short-term risk, LUCD is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check INSP's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, ATEC has a market cap of 2.4B. Regarding current trading prices, LUCD is priced at $1.10, while ATEC trades at $16.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas ATEC's P/E ratio is -14.28. In terms of profitability, LUCD's ROE is -4.04%, compared to ATEC's ROE of -2.52%. Regarding short-term risk, LUCD is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check ATEC's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, PRCT has a market cap of 2.3B. Regarding current trading prices, LUCD is priced at $1.10, while PRCT trades at $41.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas PRCT's P/E ratio is -26.77. In terms of profitability, LUCD's ROE is -4.04%, compared to PRCT's ROE of -0.24%. Regarding short-term risk, LUCD is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check PRCT's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, AORT has a market cap of 2.1B. Regarding current trading prices, LUCD is priced at $1.10, while AORT trades at $44.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas AORT's P/E ratio is -104.26. In terms of profitability, LUCD's ROE is -4.04%, compared to AORT's ROE of -0.06%. Regarding short-term risk, LUCD is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check AORT's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, LUCD is priced at $1.10, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas NUVA's P/E ratio is 75.00. In terms of profitability, LUCD's ROE is -4.04%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, LUCD is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check NUVA's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, LUCD is priced at $1.10, while UFPT trades at $225.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas UFPT's P/E ratio is 26.16. In terms of profitability, LUCD's ROE is -4.04%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, LUCD is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check UFPT's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, CNMD has a market cap of 1.7B. Regarding current trading prices, LUCD is priced at $1.10, while CNMD trades at $55.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas CNMD's P/E ratio is 15.77. In terms of profitability, LUCD's ROE is -4.04%, compared to CNMD's ROE of +0.11%. Regarding short-term risk, LUCD is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check CNMD's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, SSII has a market cap of 1.4B. Regarding current trading prices, LUCD is priced at $1.10, while SSII trades at $6.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas SSII's P/E ratio is -116.50. In terms of profitability, LUCD's ROE is -4.04%, compared to SSII's ROE of -0.71%. Regarding short-term risk, LUCD is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check SSII's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, LUCD is priced at $1.10, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas HSKA's P/E ratio is -62.49. In terms of profitability, LUCD's ROE is -4.04%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, LUCD is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check HSKA's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, LUCD is priced at $1.10, while AHCO trades at $9.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas AHCO's P/E ratio is 17.79. In terms of profitability, LUCD's ROE is -4.04%, compared to AHCO's ROE of +0.05%. Regarding short-term risk, LUCD is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check AHCO's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, ESTA has a market cap of 1.3B. Regarding current trading prices, LUCD is priced at $1.10, while ESTA trades at $43.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas ESTA's P/E ratio is -14.17. In terms of profitability, LUCD's ROE is -4.04%, compared to ESTA's ROE of -2.41%. Regarding short-term risk, LUCD is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check ESTA's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, LUCD is priced at $1.10, while IART trades at $14.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas IART's P/E ratio is -2.27. In terms of profitability, LUCD's ROE is -4.04%, compared to IART's ROE of -0.36%. Regarding short-term risk, LUCD is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check IART's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, LUCD is priced at $1.10, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas SILK's P/E ratio is -18.96. In terms of profitability, LUCD's ROE is -4.04%, compared to SILK's ROE of -0.20%. Regarding short-term risk, LUCD is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check SILK's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, LUCD is priced at $1.10, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas FNA's P/E ratio is -19.83. In terms of profitability, LUCD's ROE is -4.04%, compared to FNA's ROE of -0.36%. Regarding short-term risk, LUCD is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check FNA's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, INMD has a market cap of 1B. Regarding current trading prices, LUCD is priced at $1.10, while INMD trades at $14.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas INMD's P/E ratio is 6.22. In terms of profitability, LUCD's ROE is -4.04%, compared to INMD's ROE of +0.27%. Regarding short-term risk, LUCD is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check INMD's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, IRMD has a market cap of 924.2M. Regarding current trading prices, LUCD is priced at $1.10, while IRMD trades at $72.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas IRMD's P/E ratio is 45.13. In terms of profitability, LUCD's ROE is -4.04%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, LUCD is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check IRMD's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, LUCD is priced at $1.10, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas CSII's P/E ratio is -20.83. In terms of profitability, LUCD's ROE is -4.04%, compared to CSII's ROE of -0.14%. Regarding short-term risk, LUCD is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check CSII's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, TNDM has a market cap of 806.1M. Regarding current trading prices, LUCD is priced at $1.10, while TNDM trades at $11.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas TNDM's P/E ratio is -3.87. In terms of profitability, LUCD's ROE is -4.04%, compared to TNDM's ROE of -1.04%. Regarding short-term risk, LUCD is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check TNDM's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, AXGN has a market cap of 748.2M. Regarding current trading prices, LUCD is priced at $1.10, while AXGN trades at $16.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas AXGN's P/E ratio is -162.60. In terms of profitability, LUCD's ROE is -4.04%, compared to AXGN's ROE of -0.04%. Regarding short-term risk, LUCD is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check AXGN's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, LUCD is priced at $1.10, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas CRY's P/E ratio is 425.71. In terms of profitability, LUCD's ROE is -4.04%, compared to CRY's ROE of -0.05%. Regarding short-term risk, LUCD is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check CRY's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, SIBN has a market cap of 707.1M. Regarding current trading prices, LUCD is priced at $1.10, while SIBN trades at $16.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas SIBN's P/E ratio is -28.75. In terms of profitability, LUCD's ROE is -4.04%, compared to SIBN's ROE of -0.14%. Regarding short-term risk, LUCD is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check SIBN's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, LUCD is priced at $1.10, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas APEN's P/E ratio is -9.43. In terms of profitability, LUCD's ROE is -4.04%, compared to APEN's ROE of -0.85%. Regarding short-term risk, LUCD is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check APEN's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, OFIX has a market cap of 574.6M. Regarding current trading prices, LUCD is priced at $1.10, while OFIX trades at $14.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas OFIX's P/E ratio is -4.59. In terms of profitability, LUCD's ROE is -4.04%, compared to OFIX's ROE of -0.25%. Regarding short-term risk, LUCD is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check OFIX's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, AVNS has a market cap of 542.9M. Regarding current trading prices, LUCD is priced at $1.10, while AVNS trades at $11.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas AVNS's P/E ratio is -1.17. In terms of profitability, LUCD's ROE is -4.04%, compared to AVNS's ROE of -0.50%. Regarding short-term risk, LUCD is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check AVNS's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, ZIMV has a market cap of 534.4M. Regarding current trading prices, LUCD is priced at $1.10, while ZIMV trades at $18.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas ZIMV's P/E ratio is -27.46. In terms of profitability, LUCD's ROE is -4.04%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, LUCD is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check ZIMV's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, SRDX has a market cap of 531.7M. Regarding current trading prices, LUCD is priced at $1.10, while SRDX trades at $37.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas SRDX's P/E ratio is -29.99. In terms of profitability, LUCD's ROE is -4.04%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, LUCD is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check SRDX's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, CTKB has a market cap of 528M. Regarding current trading prices, LUCD is priced at $1.10, while CTKB trades at $4.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas CTKB's P/E ratio is -83.00. In terms of profitability, LUCD's ROE is -4.04%, compared to CTKB's ROE of -0.02%. Regarding short-term risk, LUCD is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check CTKB's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, BVS has a market cap of 511.1M. Regarding current trading prices, LUCD is priced at $1.10, while BVS trades at $7.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas BVS's P/E ratio is 254.67. In terms of profitability, LUCD's ROE is -4.04%, compared to BVS's ROE of -0.00%. Regarding short-term risk, LUCD is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check BVS's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, KIDS has a market cap of 506.5M. Regarding current trading prices, LUCD is priced at $1.10, while KIDS trades at $20.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas KIDS's P/E ratio is -11.22. In terms of profitability, LUCD's ROE is -4.04%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, LUCD is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check KIDS's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, TMCI has a market cap of 486.4M. Regarding current trading prices, LUCD is priced at $1.10, while TMCI trades at $7.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas TMCI's P/E ratio is -9.75. In terms of profitability, LUCD's ROE is -4.04%, compared to TMCI's ROE of -0.47%. Regarding short-term risk, LUCD is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check TMCI's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, VREX has a market cap of 482.2M. Regarding current trading prices, LUCD is priced at $1.10, while VREX trades at $11.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas VREX's P/E ratio is -3.60. In terms of profitability, LUCD's ROE is -4.04%, compared to VREX's ROE of -0.25%. Regarding short-term risk, LUCD is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check VREX's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, SMLR has a market cap of 465.3M. Regarding current trading prices, LUCD is priced at $1.10, while SMLR trades at $31.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas SMLR's P/E ratio is 6.89. In terms of profitability, LUCD's ROE is -4.04%, compared to SMLR's ROE of +0.17%. Regarding short-term risk, LUCD is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check SMLR's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, CBLL has a market cap of 442.2M. Regarding current trading prices, LUCD is priced at $1.10, while CBLL trades at $12.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas CBLL's P/E ratio is -3.34. In terms of profitability, LUCD's ROE is -4.04%, compared to CBLL's ROE of -0.48%. Regarding short-term risk, LUCD is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check CBLL's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, PACB has a market cap of 414.5M. Regarding current trading prices, LUCD is priced at $1.10, while PACB trades at $1.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas PACB's P/E ratio is -0.62. In terms of profitability, LUCD's ROE is -4.04%, compared to PACB's ROE of -1.89%. Regarding short-term risk, LUCD is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check PACB's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, SNWV has a market cap of 385.6M. Regarding current trading prices, LUCD is priced at $1.10, while SNWV trades at $45.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas SNWV's P/E ratio is -5.47. In terms of profitability, LUCD's ROE is -4.04%, compared to SNWV's ROE of +1.45%. Regarding short-term risk, LUCD is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check SNWV's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, BFLY has a market cap of 382.6M. Regarding current trading prices, LUCD is priced at $1.10, while BFLY trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas BFLY's P/E ratio is -5.43. In terms of profitability, LUCD's ROE is -4.04%, compared to BFLY's ROE of -0.31%. Regarding short-term risk, LUCD is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check BFLY's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, RXST has a market cap of 379.7M. Regarding current trading prices, LUCD is priced at $1.10, while RXST trades at $9.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas RXST's P/E ratio is -11.60. In terms of profitability, LUCD's ROE is -4.04%, compared to RXST's ROE of -0.12%. Regarding short-term risk, LUCD is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check RXST's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, SENS has a market cap of 375.6M. Regarding current trading prices, LUCD is priced at $1.10, while SENS trades at $0.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas SENS's P/E ratio is -4.61. In terms of profitability, LUCD's ROE is -4.04%, compared to SENS's ROE of -12.27%. Regarding short-term risk, LUCD is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check SENS's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, BFLY-WT has a market cap of 362.7M. Regarding current trading prices, LUCD is priced at $1.10, while BFLY-WT trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, LUCD's ROE is -4.04%, compared to BFLY-WT's ROE of -0.31%. Regarding short-term risk, LUCD is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check BFLY-WT's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, CLPT has a market cap of 304.2M. Regarding current trading prices, LUCD is priced at $1.10, while CLPT trades at $10.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas CLPT's P/E ratio is -13.37. In terms of profitability, LUCD's ROE is -4.04%, compared to CLPT's ROE of -0.94%. Regarding short-term risk, LUCD is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check CLPT's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, NPCE has a market cap of 297.4M. Regarding current trading prices, LUCD is priced at $1.10, while NPCE trades at $8.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas NPCE's P/E ratio is -10.96. In terms of profitability, LUCD's ROE is -4.04%, compared to NPCE's ROE of -1.12%. Regarding short-term risk, LUCD is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check NPCE's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, TCMD has a market cap of 294.9M. Regarding current trading prices, LUCD is priced at $1.10, while TCMD trades at $13.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas TCMD's P/E ratio is 21.34. In terms of profitability, LUCD's ROE is -4.04%, compared to TCMD's ROE of +0.07%. Regarding short-term risk, LUCD is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check TCMD's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, BWAY has a market cap of 287.3M. Regarding current trading prices, LUCD is priced at $1.10, while BWAY trades at $15.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas BWAY's P/E ratio is 54.29. In terms of profitability, LUCD's ROE is -4.04%, compared to BWAY's ROE of +0.09%. Regarding short-term risk, LUCD is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check BWAY's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, VMD has a market cap of 283.5M. Regarding current trading prices, LUCD is priced at $1.10, while VMD trades at $7.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas VMD's P/E ratio is 21.50. In terms of profitability, LUCD's ROE is -4.04%, compared to VMD's ROE of +0.11%. Regarding short-term risk, LUCD is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check VMD's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, CATX has a market cap of 272.9M. Regarding current trading prices, LUCD is priced at $1.10, while CATX trades at $3.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas CATX's P/E ratio is -2.68. In terms of profitability, LUCD's ROE is -4.04%, compared to CATX's ROE of -0.32%. Regarding short-term risk, LUCD is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check CATX's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, NNOX has a market cap of 258.9M. Regarding current trading prices, LUCD is priced at $1.10, while NNOX trades at $4.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas NNOX's P/E ratio is -4.51. In terms of profitability, LUCD's ROE is -4.04%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, LUCD is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check NNOX's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, OM has a market cap of 252.3M. Regarding current trading prices, LUCD is priced at $1.10, while OM trades at $14.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas OM's P/E ratio is -0.76. In terms of profitability, LUCD's ROE is -4.04%, compared to OM's ROE of -0.98%. Regarding short-term risk, LUCD is more volatile compared to OM. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check OM's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, CERS has a market cap of 242.5M. Regarding current trading prices, LUCD is priced at $1.10, while CERS trades at $1.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas CERS's P/E ratio is -12.65. In terms of profitability, LUCD's ROE is -4.04%, compared to CERS's ROE of -0.34%. Regarding short-term risk, LUCD is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check CERS's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, MASS has a market cap of 232.8M. Regarding current trading prices, LUCD is priced at $1.10, while MASS trades at $6.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas MASS's P/E ratio is -2.73. In terms of profitability, LUCD's ROE is -4.04%, compared to MASS's ROE of -0.13%. Regarding short-term risk, LUCD is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check MASS's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, QTRX has a market cap of 224.4M. Regarding current trading prices, LUCD is priced at $1.10, while QTRX trades at $4.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas QTRX's P/E ratio is -2.67. In terms of profitability, LUCD's ROE is -4.04%, compared to QTRX's ROE of -0.22%. Regarding short-term risk, LUCD is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check QTRX's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, LUCD is priced at $1.10, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas NVRO's P/E ratio is -1.91. In terms of profitability, LUCD's ROE is -4.04%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, LUCD is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check NVRO's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, SGHT has a market cap of 221.5M. Regarding current trading prices, LUCD is priced at $1.10, while SGHT trades at $4.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas SGHT's P/E ratio is -4.41. In terms of profitability, LUCD's ROE is -4.04%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, LUCD is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check SGHT's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, LUCD is priced at $1.10, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas EYES's P/E ratio is N/A. In terms of profitability, LUCD's ROE is -4.04%, compared to EYES's ROE of -0.26%. Regarding short-term risk, LUCD is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check EYES's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, INGN has a market cap of 209.6M. Regarding current trading prices, LUCD is priced at $1.10, while INGN trades at $7.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas INGN's P/E ratio is -7.31. In terms of profitability, LUCD's ROE is -4.04%, compared to INGN's ROE of -0.14%. Regarding short-term risk, LUCD is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check INGN's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, CVRX has a market cap of 204M. Regarding current trading prices, LUCD is priced at $1.10, while CVRX trades at $7.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas CVRX's P/E ratio is -3.79. In terms of profitability, LUCD's ROE is -4.04%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, LUCD is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check CVRX's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, MGRM has a market cap of 197.1M. Regarding current trading prices, LUCD is priced at $1.10, while MGRM trades at $5.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas MGRM's P/E ratio is -10.09. In terms of profitability, LUCD's ROE is -4.04%, compared to MGRM's ROE of -1.37%. Regarding short-term risk, LUCD is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check MGRM's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, TLSI has a market cap of 191.8M. Regarding current trading prices, LUCD is priced at $1.10, while TLSI trades at $5.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas TLSI's P/E ratio is -4.39. In terms of profitability, LUCD's ROE is -4.04%, compared to TLSI's ROE of +1.27%. Regarding short-term risk, LUCD is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check TLSI's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, ELMD has a market cap of 169.1M. Regarding current trading prices, LUCD is priced at $1.10, while ELMD trades at $20.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas ELMD's P/E ratio is 25.53. In terms of profitability, LUCD's ROE is -4.04%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, LUCD is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check ELMD's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, BSGM has a market cap of 162.3M. Regarding current trading prices, LUCD is priced at $1.10, while BSGM trades at $5.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas BSGM's P/E ratio is -4.93. In terms of profitability, LUCD's ROE is -4.04%, compared to BSGM's ROE of +41.24%. Regarding short-term risk, LUCD is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check BSGM's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, LNSR has a market cap of 154M. Regarding current trading prices, LUCD is priced at $1.10, while LNSR trades at $12.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas LNSR's P/E ratio is -3.06. In terms of profitability, LUCD's ROE is -4.04%, compared to LNSR's ROE of +51.79%. Regarding short-term risk, LUCD is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check LNSR's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, MXCT has a market cap of 151.4M. Regarding current trading prices, LUCD is priced at $1.10, while MXCT trades at $1.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas MXCT's P/E ratio is -3.38. In terms of profitability, LUCD's ROE is -4.04%, compared to MXCT's ROE of -0.22%. Regarding short-term risk, LUCD is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check MXCT's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, AVR has a market cap of 149.3M. Regarding current trading prices, LUCD is priced at $1.10, while AVR trades at $4.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas AVR's P/E ratio is -1.36. In terms of profitability, LUCD's ROE is -4.04%, compared to AVR's ROE of -2.52%. Regarding short-term risk, LUCD is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check AVR's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, PROF has a market cap of 142.5M. Regarding current trading prices, LUCD is priced at $1.10, while PROF trades at $4.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas PROF's P/E ratio is -3.27. In terms of profitability, LUCD's ROE is -4.04%, compared to PROF's ROE of -0.91%. Regarding short-term risk, LUCD is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check PROF's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, ANIK has a market cap of 139.1M. Regarding current trading prices, LUCD is priced at $1.10, while ANIK trades at $9.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas ANIK's P/E ratio is -10.72. In terms of profitability, LUCD's ROE is -4.04%, compared to ANIK's ROE of -0.38%. Regarding short-term risk, LUCD is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check ANIK's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, RCEL has a market cap of 130M. Regarding current trading prices, LUCD is priced at $1.10, while RCEL trades at $4.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas RCEL's P/E ratio is -2.48. In terms of profitability, LUCD's ROE is -4.04%, compared to RCEL's ROE of +279.91%. Regarding short-term risk, LUCD is more volatile compared to RCEL. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check RCEL's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, OWLT has a market cap of 128.9M. Regarding current trading prices, LUCD is priced at $1.10, while OWLT trades at $7.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas OWLT's P/E ratio is -2.02. In terms of profitability, LUCD's ROE is -4.04%, compared to OWLT's ROE of +2.12%. Regarding short-term risk, LUCD is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check OWLT's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, RPID has a market cap of 125.5M. Regarding current trading prices, LUCD is priced at $1.10, while RPID trades at $2.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas RPID's P/E ratio is -2.85. In terms of profitability, LUCD's ROE is -4.04%, compared to RPID's ROE of -0.63%. Regarding short-term risk, LUCD is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for LUCD.Check RPID's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, LUCD is priced at $1.10, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas ICAD's P/E ratio is -20.37. In terms of profitability, LUCD's ROE is -4.04%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, LUCD is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check ICAD's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, HYPR has a market cap of 101.8M. Regarding current trading prices, LUCD is priced at $1.10, while HYPR trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas HYPR's P/E ratio is -2.49. In terms of profitability, LUCD's ROE is -4.04%, compared to HYPR's ROE of -0.85%. Regarding short-term risk, LUCD is more volatile compared to HYPR. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check HYPR's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, NSPR has a market cap of 99.1M. Regarding current trading prices, LUCD is priced at $1.10, while NSPR trades at $2.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas NSPR's P/E ratio is -2.93. In terms of profitability, LUCD's ROE is -4.04%, compared to NSPR's ROE of -1.31%. Regarding short-term risk, LUCD is more volatile compared to NSPR. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check NSPR's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, LUCD is priced at $1.10, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas HJLI's P/E ratio is N/A. In terms of profitability, LUCD's ROE is -4.04%, compared to HJLI's ROE of -0.00%. Regarding short-term risk, LUCD is more volatile compared to HJLI. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check HJLI's competition here

LUCD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUCD stands at 119.3M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, LUCD is priced at $1.10, while ASXC trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUCD currently has a P/E ratio of -1.16, whereas ASXC's P/E ratio is -1.12. In terms of profitability, LUCD's ROE is -4.04%, compared to ASXC's ROE of -56.86%. Regarding short-term risk, LUCD is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for LUCD.Check ASXC's competition here